{
    "id": 3284,
    "name": "thymic carcinoma",
    "source": "DOID",
    "definition": "A thymus cancer that derives_from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found. [url:http\\://www.cancer.gov/cancertopics/pdq/treatment/thymoma/patient/page1]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3284",
    "evidence": [
        {
            "id": 6746,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with thymic carcinoma harboring KIT D579del achieved disease stabilization following treatment with Gleevec (imatinib) (PMID: 24419427).",
            "molecularProfile": {
                "id": 1700,
                "profileName": "KIT D579del"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5812,
                    "pubMedId": 24419427,
                    "title": "Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24419427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6747,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic thymic carcinoma harboring KIT Y553N demonstrated improved clinical performance and reduction in metastatic lesions following treatment with Gleevec (imatinib) (PMID: 21969494).",
            "molecularProfile": {
                "id": 3216,
                "profileName": "KIT Y553N"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5813,
                    "pubMedId": 21969494,
                    "title": "Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21969494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6748,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT V560del with KIT over expression initially demonstrated stable disease and reduction in metastatic lesions following treatment with Gleevec (imatinib), but progressed after 6 months (PMID: 15201427).",
            "molecularProfile": {
                "id": 23682,
                "profileName": "KIT V560del KIT over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5814,
                    "pubMedId": 15201427,
                    "title": "Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15201427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6749,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876).",
            "molecularProfile": {
                "id": 23683,
                "profileName": "KIT P577_D579del"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5815,
                    "pubMedId": 20970876,
                    "title": "Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20970876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6750,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405).",
            "molecularProfile": {
                "id": 4900,
                "profileName": "KIT D820E"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5817,
                    "pubMedId": 19461405,
                    "title": "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19461405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12226,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selinexor (KPT-330) induced cell-cycle arrest and apoptosis and inhibited growth of several thymic epithelial tumor cell lines, including thymoma and thymic carcinoma cell lines, in culture, and inhibited tumor growth in thymic carcinoma cell line xenograft models (PMID: 28819023).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10184,
                    "pubMedId": 28819023,
                    "title": "Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819023"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12227,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of XPO1 was associated with acquired resistance to Selinexor (KPT-330) in a thymic carcinoma cell line in culture (PMID: 28819023).",
            "molecularProfile": {
                "id": 28567,
                "profileName": "XPO1 amp"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10184,
                    "pubMedId": 28819023,
                    "title": "Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14478,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MINT1526A in combination with Avastin (bevacizumab) resulted in partial response in a patient with thymic carcinoma (PMID: 29905898).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7095,
                "therapyName": "Bevacizumab + MINT1526A",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11646,
                    "pubMedId": 29905898,
                    "title": "Phase I study of the anti-\u03b15\u03b21 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29905898"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20013,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in an response rate of 22.5% (9/40, 1 complete response, 8 partial response), and stable disease in 53% (21/40) of patients with recurrent thymic carcinoma, however, severe immune toxicity was seen in 15% (6/41) of the patients (PMID: 29395863; NCT02364076).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17656,
                    "pubMedId": 29395863,
                    "title": "Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29395863"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20011,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in partial response in 19.2% (5/26) and stable disease in 53.8% (14/26) of patients with refractory or relapsed thymic carcinoma, with a median progression-free survival of 6.1 months, however, grade 3 or higher immune-related adverse events were seen in 15.4% (4/26) of the patients (PMID: 29906252).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17654,
                    "pubMedId": 29906252,
                    "title": "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906252"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01011439",
            "title": "Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2654,
                    "therapyName": "Milciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01025089",
            "title": "Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 1927,
                    "therapyName": "Cisplatin + Cyclophosphamide + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01301391",
            "title": "Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2654,
                    "therapyName": "Milciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01396408",
            "title": "A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01621568",
            "title": "Sunitinib for Advanced Thymus Cancer Following Earlier Treatment",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02364076",
            "title": "Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02824042",
            "title": "Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4594,
                    "therapyName": "Anetumab ravtansine + Itraconazole",
                    "synonyms": null
                },
                {
                    "id": 4593,
                    "therapyName": "Anetumab ravtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03076554",
            "title": "A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03193437",
            "title": "Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03295227",
            "title": "Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03463460",
            "title": "Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6788,
                    "therapyName": "Pembrolizumab + Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03556228",
            "title": "Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9610,
                    "therapyName": "VMD-928",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03583086",
            "title": "H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6916,
                    "therapyName": "Nivolumab + Vorolanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694002",
            "title": "Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1726,
                    "therapyName": "Carboplatin + Paclitaxel + Ramucirumab",
                    "synonyms": null
                }
            ]
        }
    ]
}